Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACH-000029 SAD Study in Healthy Volunteers
NCT05363839Phase 1Terminated
- Sponsor
- Syneos Health
- Start
- May 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACH-000029 in Autism Spectrum Disorder (ASD), sponsored by Syneos Health. Primary endpoints: Number (%) of subjects experiencing orthostatic hypotension at Day 7 and Maximum change in timepoint-matched systolic blood pressure and diastolic blood pressure at Day 7. Started May 2022; status: terminated.
02
Drugs
ACH-000029
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05363839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363839.